Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 9:8:100294.
doi: 10.1016/j.ajpc.2021.100294. eCollection 2021 Dec.

The impact of lipid-lowering medications on coronary artery plaque characteristics

Vishnu Priya Pulipati  1 , Francis J Alenghat  1   2
Affiliations

The impact of lipid-lowering medications on coronary artery plaque characteristics

Vishnu Priya Pulipati et al. Am J Prev Cardiol. .

Abstract

Atherosclerosis is the predominant cause of coronary artery disease. The last several decades have witnessed significant advances in lipid-lowering therapies, which comprise a central component of atherosclerotic cardiovascular disease prevention. In addition to cardiovascular risk reduction with dyslipidemia management, some lipid-based therapies show promise at the level of the atherosclerotic plaque itself through mechanisms governing lipid accumulation, plaque stability, local inflammation, endothelial dysfunction, and thrombogenicity. The capacity of lipid-lowering therapies to modify atherosclerotic plaque burden, size, composition, and vulnerability should correlate with their ability to reduce disease progression. This review discusses plaque characteristics, diagnostic modalities to evaluate these characteristics, and how they are altered by current and emerging lipid-lowering therapies, all in human coronary artery disease.

Keywords: Atherosclerosis; Cardiovascular disease; Lipids; Plaque; Prevention; Therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. World Health Organization: The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death [Updated 12/2020].
    1. Manduteanu I., Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med. 2012;16(9):1978–1990. doi: 10.1111/j.1582-4934.2012.01552.x. - DOI - PMC - PubMed
    1. Navarese E.P., Robinson J.G., Kowalewski M., et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1566–1579. doi: 10.1001/jama.2018.2525. - DOI - PMC - PubMed
    1. Ray K.K., Ginsberg H.N., Davidson M.H., et al. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016;134(24):1931–1943. doi: 10.1161/CIRCULATIONAHA.116.024604. - DOI - PMC - PubMed
    1. Gibson M.S., Domingues N., Vieira O.V. Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis. Front Physiol. 2018;9:654. doi: 10.3389/fphys.2018.00654. - DOI - PMC - PubMed

LinkOut - more resources